163 results on '"Castellano, D."'
Search Results
2. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
3. P-042 SHORT-TERM RESULTS OF LAPAROSCOPIC TOTALLY EXTRAPERITONEAL (TEP) GROIN HERNIA REPAIR WITH LIGHTWEIGHT FLAT MESH WITHOUT FIXATION. AGAINST THE ESTABLISHED?
4. P-028 SHORT-TERM RESULTS OF LAPAROSCOPIC INTRACORPOREAL RECTUS APONEUROPLASTY (LIRA). OUR FIRST EXPERIENCES
5. IMvigor010: Updated analysis of Overall Survival (OS) by circulating tumour DNA (ctDNA) status in patients with post-operative Muscle-Invasive Urothelial Carcinoma (MIUC) treated with atezolizumab
6. Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study
7. Extraordinary selection on the human X chromosome associated with archaic admixture
8. Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
9. Corrigendum to “589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)”
10. Qualité de vie et symptômes chez les patients atteints d’un carcinome urothélial localement avancé ou métastatique précédemment traité de l’étude Ev-301 : une étude randomisée de phase 3 comparant enfortumab vedotin à la chimiothérapie
11. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
12. 716TiP IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy
13. 698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma
14. 662P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced non–clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B
15. 1097O The AXINET trial (GETNE1107): Axitinib plus octreotide LAR improves PFS by blinded central radiological assessment vs placebo plus octreotide LAR in G1-2 extrapancreatic NETs
16. 685P Genome-wide association meta-analysis identifies novel variants that correlate with efficacy outcomes in sunitinib-treated patients with metastatic renal cell carcinoma
17. SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy
18. Pneumatosis intestinalis in a radioactive iodine-refractory metastasic thyroid papillary carcinoma with BRAFV600E mutation treated with dabrafenib–trametinib: a case report
19. Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future
20. CtDNA as a predictor of outcome in patients treated with neoadjuvant atezolizumab in muscle invasive urothelial cancer
21. 1O Clinical outcomes in post-operative ctDNA-positive muscle-invasive urothelial carcinoma (MIUC) patients after atezolizumab adjuvant therapy
22. 199O A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis
23. Nivolumab + ipilimumab (N + I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés
24. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
25. 709P Cabozantinib (C) in combination with atezolizumab (A) in non-clear cell renal cell carcinoma (nccRCC): Results from cohort 10 of the COSMIC-021 study
26. Venous thromboembolic events stratified by number of risk factors in patients with metastatic germ cell tumours undergoing first-line chemotherapy
27. Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group
28. Dust Environment Model of the Interstellar Comet 2I/Borisov
29. Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials
30. Polycaprolactone/gelatin-based scaffolds with tailored performance: in vitro and in vivo validation
31. Double Immune Checkpoint Blockade in Renal Cell Carcinoma
32. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
33. CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC)
34. Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study
35. Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD
36. Immunohistochemistry-based taxonomical classification of bladder cancer predicts response to neoadjuvant chemotherapy
37. FIERCE-21: Phase 2 study of vofatamab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUCC)
38. Strong selective sweeps before 45,000BP displaced archaic admixture across the human X chromosome
39. Efficacy of therapies after progression to up-front docetaxel (D) with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC)
40. RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results
41. A phase II study investigating the safety and efficacy of neoadjuvent atezolizumab in muscle invasive bladder cancer (ABACUS)
42. Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel
43. In vitro validation of biomedical polyester-based scaffolds: Poly(lactide-co-glycolide) as model-case
44. Pembrolizumab (pembro) as first-line therapy in elderly patients (pts) with poor performance status with cisplatin-ineligible advanced urothelial cancer (UC): Results from Keynote-052
45. Healthcare resource utilization in RANGE: Ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced or metastatic urothelial cancer
46. Overall material usage effectiveness (OME): a structured indicator to measure the effective material usage within manufacturing processes
47. Long-Term Outcomes of Organ Preservation for Bladder Cancer in a Large Cohort
48. Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer
49. RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma
50. Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.